187 related articles for article (PubMed ID: 37583314)
1. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
Caroti KS; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Cohen AT; Brescia C; Abdelgawwad K; Psaroudakis G; Rivera M; Schaefer B; Brobert G; Coleman CI
Clin Appl Thromb Hemost; 2023; 29():10760296231189282. PubMed ID: 37583314
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI; Caroti KS; Abdelgawwad K; Psaroudakis G; Fatoba S; Rivera M; Schaefer B; Brobert G; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Brescia C; Cohen AT
JACC CardioOncol; 2023 Apr; 5(2):189-200. PubMed ID: 37144109
[TBL] [Abstract][Full Text] [Related]
4. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
5. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.
Costa OS; Kohn CG; Kuderer NM; Lyman GH; Bunz TJ; Coleman CI
Blood Adv; 2020 Sep; 4(17):4045-4051. PubMed ID: 32853381
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
9. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients.
Wu S; Guan C; Chang S; Wang C; Zhang J
Ann Pharmacother; 2024 Mar; 58(3):214-222. PubMed ID: 37312538
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Cohen AT; Wallenhorst C; Rivera M; Ay C; Schaefer B; Abdelgawwad K; Psaroudakis G; Brobert G; Ekbom A; Lee AYY; Khorana AA; Becattini C; Carrier M; Coleman CI; Martinez C
Thromb Haemost; 2024 Apr; ():. PubMed ID: 38301711
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Hakoum MB; Kahale LA; Tsolakian IG; Matar CF; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006649. PubMed ID: 29363105
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
19. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban
Kim JH; Seo S; Kim KP; Chang HM; Ryoo BY; Yoo C; Jeong JH; Lee JL; Im HS; Jeong H; Bang Y; Park SR
In Vivo; 2020; 34(2):829-837. PubMed ID: 32111791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
